Compare ARDX & CDRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARDX | CDRE |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2014 | 2021 |
| Metric | ARDX | CDRE |
|---|---|---|
| Price | $6.97 | $29.85 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $15.14 | ★ $39.67 |
| AVG Volume (30 Days) | ★ 3.8M | 357.0K |
| Earning Date | 04-30-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 1.46% |
| EPS Growth | N/A | ★ 13.33 |
| EPS | N/A | ★ 1.02 |
| Revenue | $2,607,000.00 | ★ $610,308,000.00 |
| Revenue This Year | $37.75 | $23.72 |
| Revenue Next Year | $34.24 | $6.89 |
| P/E Ratio | ★ N/A | $30.30 |
| Revenue Growth | N/A | ★ 7.53 |
| 52 Week Low | $3.54 | $27.32 |
| 52 Week High | $8.40 | $48.76 |
| Indicator | ARDX | CDRE |
|---|---|---|
| Relative Strength Index (RSI) | 62.75 | 44.54 |
| Support Level | $6.83 | $29.19 |
| Resistance Level | $8.23 | $31.48 |
| Average True Range (ATR) | 0.36 | 1.37 |
| MACD | 0.11 | 0.28 |
| Stochastic Oscillator | 69.88 | 55.69 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Cadre Holdings Inc is engaged in the design and manufacture of a diversified product portfolio of critical safety and survivability equipment to protect first responders, federal agencies, outdoor recreation, and personal protection markets. The company's equipment provides critical protection to allow its users to safely and securely perform their duties and protect those around them in hazardous or life-threatening situations. Its operations are comprised of two reportable segments: Products and Distribution.